Azienda Ospedaliera di Padova clinical trials
Azienda Ospedaliera di Padova is the lead sponsor of 9 current clinical trials in our Italy register. 8 are recruiting patients now. The most common phase is Observational. The drugs named most often in its trials are Zanubrutinib. The most-studied condition is Anti-MAG IgM-associated Demyelinating Polyneuropathy.
ClinicalTrials.gov trials by status
Trials by phase
Clinical trials sponsored by Azienda Ospedaliera di Padova
9 on ClinicalTrials.gov| Study | Phase | Status | Start | Registers |
|---|---|---|---|---|
|
Zanubritnib and Anti-MAG Neuropathy
NCT07392229 · ClinicalTrials.gov ↗ · Anti-MAG IgM-associated Demyelinating Polyneuropathy
Drug: Zanubrutinib |
Phase 2 | Recruiting | 2026-03 | Italy |
|
Robotically Assisted Surgery For Perihilar Cholangiocarcinoma: A Prospective Study
NCT06720883 · ClinicalTrials.gov ↗ · Cholangiocarcinoma Cancer, Perihilar Cholangiocarcinoma
|
Observational | Recruiting | 2024-06 | Italy |
|
Surgery for Locally Unresectable Pancreatic Cancer
NCT07241663 · ClinicalTrials.gov ↗ · Locally Advanced Pancreatic Adenocarcinoma
|
Observational | Recruiting | 2025-01 | Italy |
|
Conversion Surgery Vs. Palliative Care in Pancreatic Cancer Oligometastatic to the Liver
NCT06690528 · ClinicalTrials.gov ↗ · Pancreatic Cancer Metastatic
|
Phase 2 | Recruiting | 2024-11 | Italy |
|
An International Study on Pediatric Patients With Rare Tumors.
NCT07072143 · ClinicalTrials.gov ↗ · Paraganglioma/ Phaeochromocytoma, Melanoma and Other Malignant Neoplasms of Skin, Gastrointestinal Stromal Tumor (GIST)
|
Observational | Recruiting | 2025-01 | Italy |
|
Kidney Stiffness Measured by Ultrasound in Patients With High Blood Pressure and Healthy Volunteers
NCT07914075 · ClinicalTrials.gov ↗ · Arterial Hypertension, Chronic Kidney Disease, Primary Aldosteronism, Arterial Stenosis
|
Observational | Recruiting | 2026-08 | Italy |
|
Non Invasive Measurement With Trans Cranial Doppler Versus Invasive Measurement in Pediatric Age
NCT05340062 · ClinicalTrials.gov ↗ · Intracranial Hypertension
|
Observational | Recruiting | 2022-07 | Italy |
|
ULTRA-LAP Trial: Laparoscopic Debulking Surgery (LDS) in Advanced Ovarian Cancer
NCT05862740 · ClinicalTrials.gov ↗ · Ovarian Cancer
|
Not applicable | Recruiting | 2022-01 | Italy |
|
Early Recurrence After Surgery for Pancreatic Cancer
NCT07241676 · ClinicalTrials.gov ↗ · Pancreatic Ductal Adenocarcinoma (PDAC), Recurrent Pancreatic Adenocarcinoma
|
Observational | By invitation | 2025-10 | Italy |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.
Drugs in Azienda Ospedaliera di Padova trials
1 compoundDrugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.
Conditions in Azienda Ospedaliera di Padova trials
16 conditionsBy trial register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in Italy | 9 | 8 |
A trial with sites in more than one country appears in each of those registers.
Questions about Azienda Ospedaliera di Padova trials
How many clinical trials does Azienda Ospedaliera di Padova sponsor?
Azienda Ospedaliera di Padova is the lead sponsor of 9 current trials on ClinicalTrials.gov in our Italy register, as of the registry sync on 14 November 2026. Completed and withdrawn studies are not counted.
Are Azienda Ospedaliera di Padova trials recruiting?
Yes. 8 of its 9 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Which drugs is Azienda Ospedaliera di Padova testing?
Its current trials name 1 drug or biological as interventions. The most frequent are Zanubrutinib (1). The number in brackets is how many of its trials name each drug.
Where does this information come from?
Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.
How this page is built
Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
- EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries
This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 14 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.